Status and phase
Conditions
Treatments
About
The main purpose of this study is to evaluate the safety and immunogenicity of mRNA-1345 RSV vaccine when coadministered with a high dose (HD) quadrivalent seasonal influenza vaccine (Fluzone HD) in adults ≥65 years of age. The study will examine the impact of Fluzone HD on the immune response to mRNA-1345 against RSV-A and RSV-B, as well as the impact of mRNA-1345 on the immune response to Fluzone HD against 4 vaccine-matched Influenza A and B strains.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Participants may have one or more chronic medical diagnoses, but should be medically stable as assessed by:
A participant assigned female at birth is eligible to participate if they are postmenopausal or not a person of childbearing potential.
Key Exclusion Criteria:
Note: Other protocol-defined inclusion and/or exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
1,900 participants in 2 patient groups
Loading...
Central trial contact
Moderna Clinical Trials Support Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal